 |
 |
 |
|
|
|
December 19th, 2008
Ischemic Nephropathy: Diagnosis and Management 
Stephen C. Textor, MD
(ASN Board Review Course, August, 2008.)
Textor: What is the approach to ischemic nephropathy in 2008? What are the controversies? What is the prevalence? What is the impact of medical treatment with ACEI/ARB? What do the randomized trials show? Is revascularization still indicated? What are the clinical situations where revascularization can be defended? Are Doppler measures of resistivity helpful? What is BOLD MR?
Annual Dialysis Conference 2008
now in MP3AUDIOFILE LIST (Annual Dialysis Conference 2008)
(18 talks)
Genetics in Dialysis
Vaidyanathapuram Balakrishnan, MDD., Pecoits Filho, MD
Identifying and Recruiting Patients for Home Dialysis
Candice Requa, BSN, RN., Ann Billadeau, RN., Dorian Schatell, MS
Biocompatible Dialysis
Kul Aggarwal, MD., Carmel Hawley, MD., Richard Amerling, MD., Khaled Mohamed, MD., W. Kirt Nichols, MD., Peter Blake, MD., Anjali Saxena, MD., Wai Kei Lo, MD
PD Fundamentals: Challenging PD Patients
Kul Aggarwal, MD., Carmel Hawley, MD., Richard Amerling, MD., Khaled Mohamed, MD., W. Kirt Nichols, MD., Peter Blake, MD., Anjali Saxena, MD., Wai Kei Lo, MD
PD Fundamentals: Peritonitis
Mrinal Dasgupta, MD., Kurtis Tarwater, MD., Ali Abu-Alfa, MD
December 3rd, 2008
Disorders of Calcium and Phosphorus Metabolism
Myles Wolf, MD
(ASN Board Review Course, August, 2008.)
Wolf: How do we approach hyper- and hypocalcemia, and hyper- and hypophosphatemia in clinical practice? Case 1: An elderly woman with confusion, hypercalcemia, and polyuria. What are the likely causes of hypercalcemia in such a patient? How do we diagnose and treat? Case 2: A hypocalcemic patient with AKI who is dialyzed has a seizure. Why? Case 3: An African American woman with weakness and fibromyalgia has lowish calcium and low phosphate. How might these findings be related? How do we diagnose and treat hypocalcemic disorders? Case 4: A patient with stage 3 CKD and nephrotic syndrome who is moderately hypocalcemic on an uncorrected basis. Should we do anything about it? Case 5: Dialysis patient with a PTH of 973 and high calcium and phosphorus. How do we treat him? Case 6: Severe alcoholic goes into respiratory failure in the hospital during treament. Case 7: Woman with severe bone pain, hypophosphatemia, and muscle weakness. Could it be her FGF23 that's at fault?
ANNA CE
Lecture Free
Free CE
Managing Anemia in Chronic Kidney Disease: The Benefits to Patients 
Mary Schira, PhD, RN, ACNP, BC, CNN-P
(ANNA Fall Symposium, Chicago, IL. September, 2008.) 1.25 CNE
Schira: How does anemia develop as kidney function decreases? What are the various functions of red blood cells? What are the causes of anemia in CKD? Where does erythropoietin come from? When does it work in the lifespan of the RBC? How does inflammation affect erythropoiesis? What are the symptoms of anemia? How does KDOQI guide us to evaluate patients for anemia? What do RBC indices tell us? How does anemia lead to increased costs? What are KDOQI therapy targets? What are potential benefits of treating anemia? What are the potential risks of overtreatment? What patient factors affect anemia diagnosis and treatment?
Annual Dialysis Conference 2008
now in MP3AUDIOFILE LIST (Annual Dialysis Conference 2008)
(19 talks)
PD Fundamentals: Achieving Adequacy in PD (4 talks)
Dana Negoi, MD., Martin Schreiber, MD., Peter Blake, MB., John Burkart, MD
PD Fundamentals: Physiology (3 talks)
John Burkart, MD., Bengt Lindholm, MD., Linda McCann, RD
PD Fundamentals: The PD System (5 talks)
W. Kirt Nichols, MD., Farhan Khan, MD., Karl Nolph, MD., Lazaro Gotloib, MD., Isaac Teitelbaum, MD
PD Fundamentals: Increasing PD Utilization (3 talks)
Edward Vonesh, PhD., Dana Negoi, MD., Paul Kimmel, MD
Cardiovascular Risk in Patients with Renal Disease: Treating the Risk or Treating the Risk Factor? (4 talks)
David Gardner, MD., Kevin Dellsparger, MD., Rajnish Mehrotra, MD., Pranay Kathuria, MD
November 18th, 2008
Nephrology Quiz and Questionnaire: Fluid and Electrolyte and Glomerulonephritis Cases
Michael Emmett, MD, and Jai Radhakrishnan, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Emmett: Case 2: Was it laxative that the patient drank? The wife said it was magnesium citrate. Anyway, now he's comatose with normal electrolytes. Then his creatinine goes up and his serum osmolality does, also, with positive ketones, but no acidosis. How would you treat him? Case 6: A woman who takes Topamax for migraines presents with hyponatremia and hyperchloremic acidosis. How does topiramate affect the kidney and what indications is it being used for? Radhakrishnan: Case 4: Young AA woman with nephrotic syndrome and elevated ANA. OK, it's membranous: lupus or not? If lupus, how do we treat it? Case 8: Middle-aged female with acute fulminant GN picture and a creatinine of 10. Is it worth treating her? What if she has anti-GBM? What if she has MPO-ANCA? .
Preparing for the New Medical Director Responsibilities
Flash - slide/audio and MP3 audio
(Network 9/10 - RPA Special Symposium. October 2008.)
Overview and Introduction to the Nework Role in QAPI and CMS Compliance
Peter B. DeOreo, MD (Introduced by George Aronoff, MD and Alan S. Kliger, MD)
QAPI: Quality and Safety - The Big Picture
Alan S. Kliger, MD
The Medical Director, the IDT and the Medical Staff
J. Michael Lazarus, MD
Governance, Administrative and Supervisory Issues for the Medical Director under the New CfC
David Van Wyck, MD
Legal Implications for the Medical Director Under the New CfC
James Riley, Jr.
Panel Discussion: Rebuttals, Rejoinders and Reality
Drs. De Oreo, Kliger, Van Wyck, Lazarus and Mr. Riley. Moderators: Drs. Aronoff and Wish
Water: What's New and What to Do (Parts 1 and 2)
James Baker
(Dr. Priti Patel's talk to be added soon).
Biopsy Conference: A 60-year-old male with chronic lymphocytic leukemia and nephrotic syndrome
(Columbia University Nephrology and Pathology Faculty; October, 2008)
Male with chronic lymphocytic leukemia with increasing proteinuria over 2.5 years, from 0.8 to 1.4 to 7.2 g/day. Serum creatinine is 1.3 mg/dL with negative serologies. What is the differential diagnosis and how would you treat him?
(Edited by Jai Radhakrishnan, MD). (more...)
Annual Dialysis Conference 2008
now in MP3AUDIOFILE LIST (Annual Dialysis Conference 2008)
(16 talks)
Towards Animal Model Standardization in PD
Andrzej Breborowicz, MD., Bengt Lindholm, MD., Harold Moore, MA.,Andrzej Breborowicz, MD., Dirk Struijk, MD
The Evidence and Practice of HD
Madhukar Misra, MD., Christopher Chan, MD., Amit Sharma, MD
Theory and Practice of Anticoagulation
Anaadriana Zakarija, MD., Andrew Davenport, MD., Karl-Georg Fischer, MD., Suhail Ahmad, MD
PD and HD Controversies
Anatole Besarab, MD., Brendan McCormick, MD.,Brendan McCormick, MD., Salim Mujais, MD
Managing Comorbidites in PD Patients
Kul Aggarwal, MD., Pranay Kathuria, MD., Kamyar Kalantar-Zadeh, MD., Thomas Golper, MD
October 24th, 2008
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease
Stephen C. Textor, MD and Lance D. Dworkin, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Textor: What is significant renovascular disease? How do nephrologists vs. cardiologists vs. radiologists differ in their perspectives on this condition? What are the statistics regarding use of endovascular renal artery stenting? How does interventional treatment vary by geography? At what level of pressure drop does a stenosis affect renin levels? How do renal vascular lesions affect cardiovascular outcome? Renal outcome? Dworkin: How common is renal artery stenosis? How does it associate with other comorbidities? Survival? What are common justifications for its treatment? What are the main randomized trials of intervention vs. medical management and what did they show? What are their shortcomings? Why don't all patients respond to renin blockade? What is the impact of intervention on renal function? Does GFR correlate with extent of stenosis. Is flash pulmonary edema really related to renal artery stenosis? What about congestive heart failure? What is optimal medical therapy? What is the CORAL study and what is it designed to evaluate? How can we refer patients to this study? Note: The other 2 talks from this CNC are avaiable as audiofiles at this link.
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(43 talks - last batch!)
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease
SC Textor, BF King, LD Dworkin, SL Linas
The Genetics of FSGS
F Hildebrandt, AN Vats, F Kaskel
Nephrolithiasis 2007
EM Worcester, JC Lieske, AP Evan
No Patient Left Behind: Issues in Renal Transplantation
AB Leichtman, RS Gaston, RB Mannon, DJ Cohen
Novel Therapeutics for Fluid and Electrolyte Disorders
RW Schrier, P Gross, JG Verbalis, BF Palmer
What the Nephrologist Should Know about Vascular Access
JJ Sands, AQ Urbanes, A Asif, J Work
Basic Science for Clinicians: Cardiovascular Disease for the Nephrologist
JR Sowers, CS Wilcox, RM Mortensen, M Levi,
Renal Disease and the Metabolic Syndrome
P Muntner, KJ Mather, LF Fried
Public Policy Session: Nephrology Practice in the "Grey Zone": Exploring Industrial Influence in Clinical Practice
AS Kliger, DB Van Wyck, JP Kassirer,
Public Policy Board Forum: The Past, Present, and Future of Clinical Nephrology
J Himmelfarb, AR Nissenson, PB DeOreo, BM Straube
United States Renal Data System (USRDS) - Assessment of Quality of Care of the ESRD Population
PW Eggers, AJ Collins, RN Foley, BL Kasiske, NG Kutner
Plenary Session: Presidential Address (WL Henrich); John P. Peters Award (G Remuzzi); Genome Sequence Variation and the Inherited Basis of Type 2 Diabetes (D Altshuler)
Wl Henrich, G Remuzzi, D Altshuler
October 4th, 2008
New Insights, Treatments, and Management Strategies for ADPKD
Arlene B. Chapman, MD, and James P. Calvet, PhD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Chapman: What was the design of the CRISP study in ADPKD patients? How was progression measured? What factors are known to be associated with progression? How was cyst size measured? How did the investigators get by without gadolinium? What were factors predicting increase in cyst volume? What was found regarding liver cysts? PKD-1 vs. PKD-2? How is the renin-angiontensin system involved in ADPKD? What was the design of the HALT PKD study? What was the rationale for dual blockade? Is concomitant aldosterone blockade indicated? Calvet: What are the strategies to inhibit cyst formation in ADPKD? What are potential methods of inhibiting cell proliferation? Cyst secretion? How are CFTR and NKCC-1 involved? Is cyclic AMP good or bad for PKD? What about bumetanide? How does intracellular calcium act to affect cell proliferation? What are potential implications regarding calcium channel blockers? What are the data about manipulating B-Raf, MEK, and ERK? Note: The other 2 talks from this CNC are avaiable as audiofiles at this link.
ANNA CE
Lecture Free
Free CE
What You Can Teach Your Team About Chronic Kidney Disease-Related Mineral Bone Disorder (CKD-MBD)
Rebecca Schmidt, DO, FACP, FASN and Sharon Senft, RN-C, FNP
(ANNA National Symposium, Philadelphia, PA. April, 2008.) 1.5 CNE
Dr. Schmidt and Ms. Senft: Part One: What is happening to the prevalence of CKD? What is the incidence by race and ethnicity? What are the associated conditions? How many millions have CKD? Are they aware of it? Who is at greatest risk? What did we find in West Virginia? What can we learn from the case of a young diabetic with CKD? Part Two: What is this young patient's likely outcome? His mortality risk? What is the risk for hospitalization due to congestive heart failure? Expected remaining lifetime? How do serum calcium and serum phosphorus relate to mortality risk? What about the coronary artery calcification score? How can one assess vascular calcification? Part Three: How can we optimize outcome by intervening early in CKD- related mineral bone disorder? How can we achieve optimal bone health and minimize risk for vascular calcification? How do we manage a case with high serum phosphorus and high serum calcium? What about a case with high phosphorus and low serum calcium? When do we combine binders? What are the challenges in managing hyperphosphatemia? What is the calcium balance associated with various calcium baths? What are the advantages and disadvantages of each class of phosphate binders? What are their comparative efficacies? What is sevelamer carbonate and why might it be an improved binder? What can you teach your team about CKD-related bone mineral disorder (CKD-MBD)?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(33 talks)
NEW TREATMENTS FOR DIABETES MELLITUS: IMPLICATIONS FOR CLINICIANS
How Do We Treat Patients with Diabetes and CKD in 2007?
Robert G. Nelson, MD
Sulodexide, Antifibrotics, AGE Inhibitors, and PKC Inhibitors
Kumar Sharma, MD
PPAR Gamma and Thiazolidinediones
George L. Bakris, MD, FASN
PRACTICAL GENETICS OF RENAL CYSTIC DISEASES
ARPKD
Lisa M. Guay-Woodford, MD
ADPKD - 1 and 2
York P. Pei, MD, FASN
Tuberous Sclerosis and Von Hippel Lindau
John J. Bissler, MD
What to Advise Patients and Families with PKD
Ronald D. Perrone, MD
NEPHROLOGY QUIZ AND QUESTIONNAIRE
Vitamin D and Progression of Renal Disease: What are the Mechanisms?
Kevin J. Martin, MB, BCh, BAO, FACP
Vascular Calcification in Pre-ESRD
Craig B. Langman, MD
The Impact of Declining GFR on Bone Metabolism
Sharon M. Moe, MD, FASN
Do Calcimimetics Have a Role in Early Stage CKD?
Anthony A. Portale, MD
PRIMARY CARE ISSUES IN NEPHROLOGY
Peripheral Vascular Disease: Assessments and Approaches to Care
James B. Froehlich, MD, MPH
Update on Immunizations
Emily Blumberg, MD
Rheumatology for Nephrologists
Jonathan Kay, MD
ADDRESSING THE NEEDS OF THE NON-ADHERENT PATIENT
Non-Adherence in Hemodialysis: Does it Affect Outcome?
John E. Leggat, MD
Treating the Disruptive Dialysis Patient: A Practical, Medical, and Ethical Approach
Alvin H. Moss, MD
Transplanting the Non-Adherent Patient: Where Are We Now?
Jeremy Chapman, MBBS, MD, FRCP
The Line in the Sand: Legal Implications for the Treating Physician and Medical Director?
Robert A. Gutman, MD
ALDOSTERONE: NEW INSIGHTS IN KIDNEY HEALTH AND DISEASE
Aldosterone: Issues in Regulation of Blood Pressure and Sodium Transport
David H. Ellison, MD, FASN
Primary Hyperaldosteronism: Not Such a Rare Cause of Hypertension?
David A. Calhoun, MD
Mechanisms of Aldosterone-Mediated Fibrosis
Gerardo Gamba, MD, PhD
Progression of Renal Disease and Aldosterone Antagonists in Chronic Kidney Disease
Mark E. Rosenberg, MD
HIGH IMPACT CHANGES TO IMPROVE CARE FOR YOUR DIALYSIS PATIENTS
Sudden Death Prevention
Anthony J. Bleyer, MD, MS, FASN
Catheter Lock Solutions
Michael Allon, MD
Changing Practices with Nutritional Interventions
Ashwini R. Sehgal, MD
Addressing End-of-Life Issues
Jean L. Holley, MD
DILEMMAS IN THE TREATMENT OF GLOMERULAR DISEASES
Remission of Proteinuria in Idiopathic Nephrotic Syndrome: What is the Goal and at What Price?
Daniel C. Cattran, MD, FRCPC
Treatment of Frequently Relapsing/Steroid Dependent Minimal Change Disease
Ronald J. Hogg, MD
New Aspects of Membranous Nephropathy
Howard A. Austin, MD
Evaluation and Treatment Approach to Steroid-Resistant Primary FSGS in Adults
Alain Y. Meyrier, MD
MANAGING THE TRANSPLANT PATIENT WITH PROGRESSIVE RENAL DYSFUNCTION
When Do We Biopsy? Will the Information Help?
Lorraine C. Racusen, MD, FASN
Therapy for Antibody Mediated Rejection
James M. Gloor
Do We Need Calcineurin-Inhibitors and/or Steroids?
Robert W. Steiner, MD
September 15th, 2008
Novel Therapeutics for Fluid and Electrolyte Disorders
Joseph G. Verbalis, MD, and Biff F. Palmer, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Verbalis: What are the potential benefits of the vaptans in the treatment of SIADH? What are the proven advantages? Unproven advantages? Are there nonresponders to vaptans? If so, by what mechanism? Should vaptans be used in the treatment of acute hyponatremia? What are the potential lesser known adverse effects of hyponatremia in terms of cognitive function? Falls? Bone density? Palmer: How common is hyponatremia? What are the risk factors? How effective are the vaptans? What were the results of SALT1 and SALT2? How expensive is treatment with conivaptan? How might these high costs be justified in a hospital setting? Why does hyponatremia after vaptan treatment sometimes persist after vaptans are discontinued? What is one genetic basis of resistance to vaptans?
ANNA CE
Lecture Free
Free CE
Stabilizing Hemoglobin Levels: What's New in IV Iron and Anemia Management?
Steven Fishbane, MD; Suzann VanBuskirk, BSN, RN, CNN; Kristin Larson, RN, ANP, BNP, CNN
(ANNA National Symposium, Philadelphia, PA. April, 2008.) 1.5 CNE
VanBuskirk: How common is Hb variability in ESRD patients, and how does this correlate to outcomes? What are its possible causes? How do iron and ESA impact on red blood cell production? At what stage of erythropoiesis does each act? What is the role of hepcidin? What are the factors controlling reponse to ESA therapy? How can IV iron be used to optimize response to ESA and minimize Hb variability? Fishbane: What is the recent guidance from KDOQI, CMS, and the FDA regarding ESA therapy? What were the risks of using higher ESA dosing to target higher Hb levels identified in the normal Hct trial, the CHOIR trial, and the CREATE trial? What did the mandated black box warning say? What approach did the FDA recommend to ESA hyporesponsive patients? What should be the ESA strategy in light of the new recommendations? What does KDOQI recommend in terms of IV iron usage? Regarding serum ferritin? What did the DRIVE study show regarding using IV iron in patients with higher serum ferritin levels? Larson: How can we learn from case studies how to minimize Hb variability? What are the potential risks of higher ESA doses? How can we individual treatment with both IV iron and ESA to help maintain a stable Hb level?
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Optimizing Dialysis Modality Choices Around The World: A Review of Literature Concerning The Role of Enhanced Early Pre-ESRD Education in Choice of Renal Replacement Therapy Modality
(Vol 35/No. 4. Expires 08/31/2010)
Sharon M. Key, MSN, RN, ACNP-BC
1.5 hr
IV Iron Therapy and Anemia Management In Patients on Hemodialysis: Benefits Of a Revised CQI Strategy
(Vol 35/No. 4. Expires 08/31/2010)
Deborah Bowe, RN, CNN
1.4 hr
Smoking Cessation Therapy Considerations for Patients with Chronic Kidney Disease
(Vol 35/No. 4. Expires 08/31/2010)
Harold J. Manley, PharmD, FASN, FCCP, BCPS; Nicole M. Stack, PharmD
1.9 hr
A Successful 39-Week Pregnancy on Hemodialysis: A Case Report
(Vol 35/No. 4. Expires 08/31/2010)
Mary Coyle, MS, FNP; Elyn Sulger, BSN, RN, CNN, CNA-BC, CPHQ, LNC; Cindy Fletcher, MSW, LMSW; Diane Rouse, MS, RD, CDN
1.5 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(29 talks)
PHARMACOGENOMICS
Introduction to Pharmacogenomics
Stephen T. Turner, MD
Renal Failure with CsA/FK use in Non-Renal Transplant or ACE System
Kenneth E. Thummel, PhD
Treatment of Hypertension
Stephen T. Turner, MD
URINARY BIOMARKERS IN DIABETIC NEPHROPATHY
Making Measurements of the Urine Proteome
Kumar Sharma, MD
Urinary Protein Fragments and other Altered Protein Forms in Diabetic Nephropathy
Jon B. Klein, MD, PhD
Advanced Glycation Endproduct and Oxidative Stress Biomarkers
Katherine R. Tuttle, MD, FASN
The Measurement and Meaning of Growth Factors in the Urine
Richard E. Gilbert, MD, PhD, FRCPC
CHRONIC ALLOGRAFT DYSFUNCTION: HOW TO TURN THE TIDE
New Factors Associated with Transplant Loss
Roslyn B. Mannon, MD, FASN
Monitoring Inflammation and Fibrosis/ Drug Management
David N. Rush, MD, FASN
Multidrug Approach to Target Non-Immunologic Factors
John D. Scandling, MD
GENETICS OF NEPHROLITHIASIS
Primary Hyperoxaluria
Dawn S. Milliner, MD
Genetic Heterogeneity in Dent Disease
Steven J. Scheinman, MD, FASN
Hereditary Hypophosphatemic Rickets with Hypercalciuria: Role of the Sodium-Phosphate Cotransporter
Shoji Ichikawa, PhD
The Molecular Basis of Cystinuria
Paul R. Goodyer, MD
IS CHRONIC KIDNEY DISEASE A CORONARY HEART DISEASE RISK EQUIVALENT?
Burden of Cardiovascular Disease Risk Factors in Chronic Kidney Disease
Michael G. Shlipak, MD
Decreased GFR and Albuminuria: The Individual and Combined Risk with Incident CVD
Brad C. Astor, PhD, MPH
Risk of Stroke in Chronic Kidney Disease
Daniel E. Weiner, MD
Public Health Implications of CKD as a CHD Risk Equivalent
Paul Muntner, PhD
SPECTRUM OF CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE FROM YOUTH TO OUTCOMES
Obesity, Metabolic Syndrome and CKD
Holly J. Kramer, MD
Cardiovascular Risk factors and Mortality in Pediatric ESRD
Mark Mitsnefes, MD
Treatment of Atherosclerotic CVD in Advanced CKD
Marcello Tonelli, MD, MS
TECHNOLOGICAL ADVANCES IN RENAL REPLACEMENT THERAPY FOR ACUTE KIDNEY INJURY
Stem Cells and Renal Repair
Giovanni Camussi
The BioArtificial Kidney (or The Renal Assist Device)
William Fissell, MD
The Continuous Functioning Human Nephron
Allen R. Nissenson, MD, FASN
Continuous Renal Replacement Therapy with a Wearable Device
Victor Gura, MD
NEW INSIGHTS INTO COMMON PROBLEMS AFTER KIDNEY TRANSPLANTATION
Reproduction and Fertility
Dianne B. McKay, MD
Malignancy: The Current Immunosuppressive Impact
Bertram L. Kasiske, MD
Metabolic Bone Disease
Jose R. Weisinger, MD
Timelines: Overview of Management
Stephen J. Tomlanovich, MD
August 31st, 2008
DILEMMAS IN THE TREATMENT OF GLOMERULAR DISEASE:
Treatment of Frequently Relapsing/Steroid Dependent Minimal Change Disease (Hogg);
Evaluation and Treatment Approach to Steroid-Resistant Primary FSGS in Adults (Meyrier).
Ronald J. Hogg, MD and Alain Y. Meyrier, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Hogg: What are the long-term options to treat frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome? What is the optimal way to use steroids in such patients. What about non-corticosteroid therapies? Can treatment be stopped? If so, when? What is the role for cyclosporine and mycophenolate in such patients? Meyrier: How do we treat steroid-resistant, primary FSGS in adults? How do we rule out secondary FSGS? When do we look for familial (genetic) disease, and how? Does histopathology matter? What is the response to corticosteroids? What is undertreatment? What is overtreatment? What are the roles of alkylating agents, tacrolimus, cyclosporine, sirolimus, MMF, and rituximab?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(30 talks)
PREVENTION AND TREATMENT OF HUMAN ACUTE KIDNEY: BREAKING DOWN THE BARRIERS
Evolving Conceptual Model for Human AKI
Ravindra L. Mehta, MD, FASN
Using Biomarkers for AKI: What, How and When?
Bruce A. Molitoris, MD
Immunomodulatory Cytokines in Human AKI
Bertrand L. Jaber, MD, FASN
Prognosis of Human AKI: Predictive Factors for Recovery and Progression
Jonathan Himmelfarb, MD
UPDATE ON THE RAS "IT'S NOT YOUR FATHER'S RENIN-ANGIOTENSIN SYSTEM"
The (Pro)Renin Receptor
Genevieve Nguyen, MD, PhD
Intrarenal vs. Systemic AT1 Receptor: Which Mediates Injury?
Steven D. Crowley, MD
ACE2 and Ang1-7 Barry M. Brenner Endowed Lectureship
Carlos M. Ferrario
ACUTE KIDNEY INJURY: CONTEMPORARY THERAPY
Evolving Practices in the Management of AKI in the ICU
Lakhmir S. Chawla, MD
Role of Intensive Renal Replacement Therapy in AKI
John A. Kellum
World-wide Practice of Extracorporeal Treatment of AKI
Zaccaria Ricci, MD
Treatment of AKI in Children: Conservative Management to RRT
Timothy E. Bunchman, MD
ADSORBENTS IN DIALYSIS
The Bases of Mass Separation and Characteristics of Sorbent Materials
Edward F. Leonard, PhD
Biocompatibility of Adsorbent Systems
Nicholas A. Hoenich, PhD
Sorbent Augmented Dialysis Systems
James F. Winchester, MD
Use of Adsorbents in ARF Therapy
Ciro Tetta
FUNCTIONAL DECLINE AND FRAILTY IN CHRONIC KIDNEY DISEASE
Physical Functioning in ESRD: Clinical Significance of Deficits and Impact of Interventions
Patricia Lynn Painter, PhD
Frailty in CKD
Michael G. Shlipak, MD
Quality of Life and Symptoms in Elderly ESRD Patients
Steven D. Weisbord, MD, FASN
MEASURES OF KIDNEY FUNCTION BEYOND CREATININE
Estimating Equations and Direct Measurements of GFR: Assessing CKD Progression
Harold I. Feldman, MD, FASN
Determining GFR in the Clinical Setting: Should We Use Estimating Equations at All?
Fernando G. Cosio, MD, FASN
NON-RENAL DIABETIC COMPLICATIONS
New Approaches to Diabetic Retinopathy
Thomas W. Gardner, MD, MS
Diabetic Neuropathy: Mechanisms and Management
Eva L. Feldman, MD, PhD
Vascular Complications of Diabetes Microvascular Versus Macrovascular Complications
John C. Rutledge, MD
REAL LIFE AFTER TRANSPLANTATION
Pregnancy after Transplant: Newer Immunosuppressive Agents and the Outcome of Pregnancy and the Offspring
Dianne B. McKay, MD
Nagging Problems after Transplant: Hair Loss, Diarrhea, Gingival Hyperplasia, Muscle Weakness, Recurrent FSGS
Deborah B. Adey, MD
Prostate Cancer and Transplant
Maxwell V. Meng, MD
MEMBRANOUS NEPHROPATHY: BENCH TO BEDSIDE
Evolution of our Understanding of Membranous Nephropathy
William G. Couser, MD, FASN
Complement Activation in Membranous Nephropathy: Can We Intervene Therapeutically
Richard J. Quigg, MD
Cellular Response to Injury in Membranous Nephropathy
Stuart J. Shankland, MD, MBChB, FRCPC, FASN
Treatment Options in MN: Towards Pathophysiology - Driven Therapies
Pierre M. Ronco, MD, PhD
August 14th, 2008
Acute Kidney Injury. Congestive Heart Failure: A Nephrologist's Disease? (Murray) and AKI Therapeutics: From Bench to Commercialisation (Molitoris)
Patrick T. Murray, MD, FASN and Bruce A. Molitoris, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Murray: What's the role of the nephrologist in caring for patients with congestive heart failure? What should the optimal interaction be between nephrologists and cardiologists? What is cardiorenal syndrome? How does pharmacotherapy of congestive heart failure impact the kidney? What is the role of ultrafitration therapy?
Molitoris: What is the role of the academic medical center in commercializing new discoveries? In particular, what was the pathway for commercialization of a new method of supravital imaging of renal function through in vivo fluorescence microscopy that was developed at Indiana University?
ANNA CE
Lecture Free
Free CE
New Perspectives on the Progression of Coronary Artery Calcification and Patient Outcomes in Chronic Kidney Disease
Wajeh Qunibi, MD, FACP and Lynda Szczech, MD, MSCE
(ANNA National Symposium, Philadelphia, PA. April, 2008.) 1.5 CE
Qunibi: How do the various phosphate binders compare in terms or their ability to control serum phosphorus in the real world? What are the population attributable risks to elevated serum phosphorus, calcium, and PTH? What is the evidence that calcium-based phosphate binder dose is linked to calcification, and to what extent might this be operating through hyperphosphatemia in noncompliant patients? What did the CARE-2 study show? What were the mortality outcomes results in RIND and DCOR? What do the 2003 KDOQI bone disease guidelines recommend regarding phosphate binders and what might be the economic implication of these recommendations? Szczech: What are the statistical issues involved when examining observational association of laboratory values (e.g. serum calcium, phosphorus, and PTH) vs. mortality? What characterizes patients with high serum phosphate? High serum calcium? What do time varying analyses of change in these values show? Are there any clinically relevant differences between calcium carbonate and calcium acetate? Which calcium-based binder types were used in the various trials -- RIND, Treat to Goal, DCOR, and CARE-2? What are the potential pitfalls of looking at intermediate outcomes in trials of phosphate binders?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
(22 talks)
Pleitropic Actions of Vitamin D: Beyond Bone Disease
R Bouillon, CF Garland, D Bikle, GM London
One Renal Biopsy is a Picture, the Second Biopsy is More a Movie: The Importance of Repeat Biopsy in the Management of Patients
S Hariharan, ISD Roberts, JC Jennette, F Ferrario
Novel Therapeutic and Diagnostic Strategies in the Treatment of Glomerular Disease
J Floege, DTM Chan, D Roccatello, HJ Anders
Novel Risk Factors for Cardivascular Disease in Chronic Kidney Disease
VS Balakrishnan and R Mehrotra
Information Technology in Dialysis
JA Sargent, M Suresh, JE Tattersall, B Savage
July 25th, 2008
Renal Disease and the Metabolic Syndrome
Paul Muntner, PhD, and Linda F. Fried, MD, MPH
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Muntner: How is metabolic syndrome defined and how do definitions vary among various organizations? What is its prevalence? How do individual components of metabolic syndrome associated with progression of CKD? What are the treatment options?
Fried: What is the evidence that statins reduce cardiovascular disease endpoints in CKD? What did the 4D study show and how cane these negative results in stage 5D patients be explained? Is there an increased risk of stroke with statins in stage 5D patients? In other patients? What is the effect of statins on progression of CKD? What are the possible mechanisms? Which types of CKD patients might be expected to get the most benefit from statins? Is there an increased risk of tubular proteinuria?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
CILIARY SIGNALING IN PKD
Assembly and Function of Cilia and Basal Bodies
Susan K. Dutcher, PhD
Polycystin Orthologues in C. elegans
Maureen M. Barr, MD
Targeting Proteins to Cilia
Gregory J. Pazour, PhD
Regulated Proteolysis of Polycystins and Fibrocystin
Gregory G. Germino, MD
EMERGING CONCEPTS FOR GENE REGULATION IN RENAL DEVELOPMENT AND DISEASE
Epigenetic Regulation of Renal Development
Gregory R. Dressler, PhD
Regulation Gene Expression in Diabetic Nephropathy by Epigenetic Modifications
Assam El-Osta, MD
Global and Gene-Specific DNA Methylation in Lupus Nephritis
Bruce C. Richardson, MD, PhD
Promoter Modules: Integrating Signaling Cascades to Transcriptional Co-Regulation
Peter J. Nelson, MD
July 7th, 2008
Nephrolithiasis: Physicochemical Factors in the Pathogenesis of Urinary Calculi (Worcester);
Nephrolithiasis: A Bacterial Disease? Evidence Supporting and Against a Role of Nanobacteria in Calcium Stone Formation (Lieske)
Elaine M. Worcester, MD, FASN; John C. Lieske, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Worcester: What are the conditions for stone formation? How is supersaturation of urine for calcium phosphate and calcium oxalate involved? What is the optimum pH? Is urine alkalinization dangerous? Do meals affect calcification risk? How is calcium apatite plaque involved and which types of stones start in this way? What are present models of hypercalciuria? Is separation into hyperabsorbers and hyperexcretors useful? How can stone formation best be prevented? Lieske: What are nanobacteria? How small are they? What species are they related to? What types of calcification are they possibly linked to in the human body? In what types of biologic specimens can they be found? Is there any way that we can inhibit their growth? Which antibiotics seem to work? What to we know about their DNA? How can they be grown in culture?
ASDIN National Meeting. February, 2008. Part 4.
Free to ASDIN members.
Flash slide/audio; MP3 audio
Review of the Anticoagulation Cascade: Heparin, Warfarin, t-PA
Kenneth Abreo, M.D
HIT and heparin alternatives in the access center
Aris Q. Urbanes M.D.
High-Output Cardiac Failure and Vascular Access
Monnie Wasse, MD, MPH
Venous Access in CKD patients
Jeffrey Hoggard, M.D.
Coding Updates
Donald Schon, MD, FACP AKDHC
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Knowledge Expectations of Patients On Dialysis Treatment
(Vol 35/No. 3. Expires 06/30/2010)
Mirkka Rantanen, MNSc, RDH; Tapio Kallio, MNSc, RN; Kirsi Johansson, PhD, RN; Sanna Salanter„, PhD, RN; Heli Virtanen, PhDc, MNSc, RN; Helena Leino-Kilpi, PhD, RN
1.5 hr
Pharmacotherapeutic Options for the Treatment of Depression in Patients With Chronic Kidney Disease
(Vol 35/No. 3. Expires 06/30/2010)
Colette B. Raymond, BScPharm, Pharm D, MSc, ACPR; Lori D. Wazny, BScPharm, Pharm D; Patricia L. Honcharik, BScPharm, Pharm D, ACPR
1.5 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
PGE: REACTIVE OXYGEN SPECIES (Part 2 of 2)
HIF-1a and Oxygen Sensing
Salvador Moncada, MD, PhD
Oxygen Sensing by the Pulmonary Vasculature
Stephen L. Archer, MD
Vascular Oxygen Sensing: Role of NADPH and Nox Oxidase
Michael S. Wolin, PhD
ROS: Activation of Signal Transduction
Henry Jay Forman, PhD
H2O2: Regulation of Protein Tyrosine Phosphatase
(Post-doctoral fellow)
Isoprostanes and Related Lipid Oxidation Products as Mediators and Markers of Oxidant Stress in Vivo
Jason D. Morrow, MD
Transgenic Approaches to Lipid and Protein Nitration Reactions in Inflammatory Processes
Bruce Freeman, PhD
H2O2 as an EDHF
David D. Gutterman, MD
Tetrahydrobiopterin and Vascular Dysfunction
Jeannette Vasquez-Vivar, PhD
Stress Dependent Regulation of FOXO Transcription Factors
Anne Brunet, PhD
June 16th, 2008
The Genetics of FSGS.
Friederich Hildebrandt MD, and Frederick J. Kaskel, MD, PhD.
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Hildebrandt: What are the most common point mutations that cause FSGS and childhood nephrotic syndrome. How and when do they present? To what extent do they respond to treatment? Are any of them steroid responsive? Are they associated with recurrence post-transplantation? Where can one turn for gene analysis when an inherited mutation is suspected in a child with nephrotic syndrome? What are the characteristics of PLCE1 mutations (phospholipase C epsilon), and what should the approach to therapy of these patients be? Kaskel: What are predictors of outcome in FSGS? What are the general treatment approaches? How should steroids be used? Does cyclophosphamide or chlorambucil have a role? What do randomized trials show in terms of cyclosporine? What is the experience with MMF? With rapamycin? Pulse dexamethasone? What is the design of the ongoing NIH/NIDDK Study and when will we have results? When is plamapheresis indicated? What do preliminary results with rituximab show?
ASDIN National Meeting. February, 2008. Part 3.
Free to ASDIN members.
Flash slide/audio; MP3 audio
Proximal radial anastomosis
Klaus Konner, M.D.
Drug Anaphylaxis - Immediate Hypersensitivity Reactions (IHR) to Radiocontrast Media (RCM)
Kenneth Abreo, M.D.
Role of CO2 Angiography in Dialysis Access Interventions
Timothy A. Pflederer, M.D.
Local Delivery Systems
Prabir Roy-Chaudhury MBBS, PhD, FRCP
Arteriovenous Fistula Thrombosis Is there a standard method?
Arif Asif, M.D.
AVF vs AVG thrombectomy
Aris Q. Urbanes M.D.
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
PGE: REACTIVE OXYGEN SPECIES (Part 1 of 2)
Recent Advances in Superoxide Detection
Raman Kalyanaraman, PhD
Nitric Oxide and Nitrosothiol Detection: The Basics
Neil Hogg, PhD
The Vascular NADPH Oxidase and Inflammation: Crossroads at the Adventitia?
Patrick J. Pagano, PhD
NADPH Oxidase Structure, Regulation, and Binding Partners
Anthony W. Segal, MB, PhD
Role of SOD in ALS: Lessons from Transgenic Mice
Joseph Beckman, PhD
CuZnSOD versus MnSOD: Biological Role and Pathophysiology
Ting-Ting Huang, PhD
Hemoxygenase: An Intracellular Antioxidant
Mahin D. Maines, PhD
Antioxidant Mechanisms of Vitamin C
Balz Frei, PhD
Antioxidant Mechanisms of Gamma- and Alpha-Tocopherols
Kenneth Hensley, PhD
Peroxiredoxins
Aron B. Fisher, MD
June 1st, 2008
Primary Care Issues in Nephrology: Peripheral Vascular Disease: Assessments and Approaches to Care (Froehlich); Rheumatology for Nephrologists (Kay).
James B. Froehlich, MD, MPH, and Jonathan Kay, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Froehlich: What are the risk factors for peripheral arterial disease (PAD) in the general population as well as in CKD patients? Who should be screened? What tests should be used for screening and diagnosis? What are the treatment options? Which drugs are useful? When is stenting indicated? Kay: What are the possible causes of monoarticular arthritis in CKD patients? Which crystals are involved? How does one treat inflammatory (rheumatoid) arthritis in CKD? How does beta-2- microglobulin disease present, and how can one treat it? What is new in terms of nephrogenic systemic fibrosis from a rheumatology perspective?
ASDIN National Meeting. February, 2008. Part Two.
Free to ASDIN members.
Flash slide/audio; MP3 audio
Update on Lock Solutions: Alternatives to Heparin & Anti-Microbial Solutions
Stephen R. Ash, MD, FACP
Femoral Catheters
Alexander S. Yevzlin, MD
Pro: Fibrin Sheath Ablation with Catheter Removal
Donald Schon, MD, FACP
Con: Fibrin Sheath Ablation with Catheter Removal
George M. Nassar, M.D.
Cephalic arch stenosis
Surendra Shenoy M.D., Ph.D
RRI Tenth International Conference on Dialysis, January, 2008. Part Five.
(Renal Research Institute 10th International Conference)
Flash slide/audio; MP3 audio
Non-osmotic sodium interaction with hypertension and tissue hydration
Jens Titze, MD
SPECIAL LECTURE: Ethical Nephrology Care: Are our incentives alligned properly?
Alan S. Kliger, MD
Red cell survival in relationship to changes in the hematocrit: more important than you think
Dominik Uehlinger, MD
Sudden death in dialysis patients
Eberhard Ritz, MD
RPA Annual Meeting. March, 2008. Session 6.
Flash slide/audio; MP3 audio
Revaluation of the G-codes - Update on the Physician Payment Survey
Robert Kossmann, MD, PC, FACP, FASN
Creating Innovation Out of Conformity: Implementing Clinical Practice Guidelines
Richard Goldman, MD
PQRI: The Decision Making Process
Suzanne Przybyla
PQRI: The Decision Making Process
David Raskin, MD
PQRI: The Decision Making Process
Lisa Simonton
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
KIDNEY TRANSPLANTATION FOR THE GENERAL NEPHROLOGIST (Part 2 of 2)
What's New in Transplant Immunology?
Kathryn Wood, MD
Pathology of Chronic Allograft Nephropathy
Parmjeet S. Randhawa, MD, FASN
Management of Chronic Allograft Nephropathy
Jeremy Chapman, MBBS, MD, FRCP
Cardiovascular Disease and Anemia in the Transplant Patient
Arjang Djamali, MD, FASN
Recurrent Disease in the Allograft
Sundaram Hariharan, MD
Viral Hepatitis in Kidney Transplantation
Paul Martin, MD
Renal Dysfunction in Non-Renal Transplants
Akinlolu O. Ojo, MD, PhD
Post Transplant Infections
Daniel C. Brennan, MD
Post Transplant Malignancies
Roslyn B. Mannon, MD, FASN
Pregnancy in the Transplant Recipient
Dianne B. McKay, MD
Post Transplant Bone Disease
Michelle A. Josephson, MD
May 15th, 2008
Mycophenolate in Lupus and Non-Glomerular Renal Diseases
Leslie M. Shaw, PhD and Gerald B. Appel, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Shaw: How is MMF metabolized? How is MPA excreted? Why is enterhepatic circulation of MPA glucuronide important, and how is it affected by intestinal bacteria and cyclosporine? What does the new MPA assay measure? What are provisional guidelines for trough levels of MPA and area under the curve for MPA in transplantation? Appel: How does ethnicity affect response of lupus nephritis to treatment? What did the major trials show in terms of MMF use for maintenance treatment of lupus nephritis as well as for induction treatment? What are the options for use of MMF with additional immunosuppressive drugs?
Achieving Control: Optimizing the Management of CKD-Anemia
Allen R. Nissenson, MD; Steven Fishbane, MD; Michael J. Germain, MD; Robert Provenzano, MD
(CME Symposium (Synermed-Penn State), March, 2008.)
Nissenson: What is the difference between target and achieved hemoglobin? What did the 2007 KDOQI anemia update recommend and what were the results of the KDOQI meta-analysis? Fishbane: In CKD, at what point should one start to treat a low Hb? What is the approach to ESA hyporesponsiveness? How can one dose iron and ESA in such a way to limit Hb variability? Why is Hb variability relevant? Germain: What are the various drugs available to stimulate red cell production? What are their pharmacokinetics? To what extent is pharmacologic half-life associated with the time course of Hb response, especially with less frequent dosing? Is Hb variability different with shorter and longer half-life drugs? How frequently should Hb be monitored? What are good strategies for ESA dosing adjustment? Provenzano: What are areas were care of predialysis CKD patients might be improved? What resources do such patients utilize? What is the cost of providing care to them? What is the opportunity for providing care to this population and maintain reimbursement to have a viable practice? What is the RPA CKD management toolkit, and how can it help in the care of these patients? What are services, revenue, and costs of a CKD clinic model?
ASDIN National Meeting. February, 2008. Part One.
Free to ASDIN members.
Flash slide/audio; MP3 audio
Vessel Mapping
Linda Francisco,M.D.
Approach in Difficult Patient: Mastectomy, Stroke Arm etc
Naveen Atray, MD, FASN.
Forearm AVG Before Upper Arm AVF
Naveen Atray, MD, FASN.
New AVG materials - Update and endovascular approach
Surendra Shenoy M.D., Ph.D.
Stent Placement
Timothy A. Pflederer, MD.
Physical Examination
Arif Asif, M.D.
RRI Tenth International Conference on Dialysis, January, 2008. Part Four.
(Renal Research Institute 10th International Conference)
Flash slide/audio; MP3 audio
Debate Part I - Guidelines have improved patient care and outcomes
Adeera Levin, MD
Debate Part II - Guidelines have done more harm than good
Richard Amerling, MD
Uremic toxins: do we know enough to explain uremia?
Raymond C. Vanholder, MD, PhD
How do various aspects of body composition seriously affect dialysis outcomes?
Peter Kotanko, MD
International differences in presentation, prevention and management of CKD in Eastern Europe
Boleslaw Rutkowski, MD, PhD
International differences in presentation, prevention and management of CKD in Latin America
Ricardo Correa-Rotter, MD
The Future is Your Business. Preparing for Changes in Nephrology Practice. Part Two of Three.
Flash - slide/audio and MP3/WMA audio
(RPA Annual Meeting, March, 2008.)
This is free to RPA members. Please look at the RPA members only section on the RPA website for access instructions.
Louis Diamond Lecture: Is Decision Support Software Worth the Investment?
Mark Graber, MD
Good Medical Practice-USA: Establishing Physician Competency
David Watt, MD, PhD, MPA
The Janus Face of Close Partnership with Industry
Nathan Levin, MD
Clear Separation will lead to best care for patients
Jonathan Himmelfarb, MD
Herding Cats: How to Manage Physicians' Teamwork
Susan Diamond, MD
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
KIDNEY TRANSPLANTATION FOR THE GENERAL NEPHROLOGIST (Part 1 of 2)
How the Immune System Recognizes an Allograft?
Milagros D. Samaniego-Picota, MD, FASN
Immunological Assessment of the Transplant Patient
Douglas J. Norman, MD
Organ Allocation Within the USA
Winfred W. Williams, MD
Options for the Sensitized Patient
Stanley C. Jordan, MD
Recipient Evaluation
David J. Cohen, MD
Living Donor Evaluation
Connie L. Davis, MD
The Pathology of Acute Allograft Dysfunction
Cynthia C. Nast, MD
Immunosuppression Trends in Transplantation
Robert S. Gaston, MD
Options for the Diabetic Renal Transplant Recipient
Martha Pavlakis, MD
Post Transplant Diabetes Mellitus
Fernando G. Cosio, MD, FASN
April 29th, 2008
Aldosterone: New Insights in Kidney Health and Disease
David A. Calhoun, MD and Mark E. Rosenberg, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Calhoun: In normotensive individuals, how do aldo levels affect the risk of incident hypertension? What is the prevalence of aldosteronism in mild, moderate, and severe or resistant hypotension? What percent of this is due to adenoma? How effective is spironolactone as an anti-hypertensive drug? By how much does it lower blood pressure? Is spironolactone more effective in those patients with primary hyperaldosteronism? What is the risk of hyperkalemia with spironolactone, and how can this be mitigated? Rosenberg: What does the animal data show about use of aldosterone blockers in various animal models of CKD and/or renal injury? What do the clinical studies of spironolactone in CKD show? At what level of GFR do we need to start monitoring most closely for hyperkalemia? In 2008, can the use of aldosterone antagonists for CKD progression prevention be recommended?
Management of Hyperphosphatemia in Patients with ESRD: A New Direction for Treatment in 2008
Wajeh Qunibi, MD, and Charles Nolan, MD
(CME Symposium (Medical Education Resources), January, 2008.)
Qunibi: How do sevelamer and acetate compare in terms of phosphate control? In terms of grams of binder needed to achieve equivalent phosphate control? The explanation for reduced progression rate of vascular calcification in the RIND and DCOR studies has been lack of calcium-loading with sevelamer. To what extent is an alternative hypothesis, that of lowering of LDL- cholesterol, consistent with the data? What are data in animal models regarding vascular calcification in CKD and the effect of calcium-based phosphate binders? In the CARE-2 study (now available on-line at the AJKD website) progression of calcification was compared between calcium acetate plus atorvastatin and sevelamer plus atorvastatin (as needed to achieve equivalent LDL levels). What were the principal findings of CARE-2? Nolan: What did Treat-to-Goal, DCOR, RIND, DCOR Revisited, and CARE-2 show with respect to both calcification and mortality? How were the mortality results different from the calcification results? What are the DOPPS data with regard to phosphate binder use and mortality? What percentage of patients do the KDOQI guidelines recommend for non-calcium containing phosphate binders? What are the relative costs of sevelamer, calcium acetate, and calcium carbonate?
RRI Tenth International Conference on Dialysis, January, 2008. Part Three.
(Renal Research Institute 10th International Conference)
Flash slide/audio; MP3 audio
Angiotensin II, interstitial inflammation and the pathogenesis of salt sensitive hypertension
Martha Franco, MD, PhD
How common is malnutrition in ESRD? An approach to diagnosis and management
Martin Kuhlmann, MD
Blind Pugh sends a black spot: The current hemoglobin controversy
Paul E. Stevens, MB, FRCP
KEYNOTE ADDRESS: The metabolic syndrome and kidney disease
Eberhard Ritz, MD
Transplant and CKD patients at the same stage of renal insufficiency: how are they the same or different?
Warren Kupin, MD, FACP
The Future is Your Business. Preparing for Changes in Nephrology Practice. Part One of Three.
Flash - slide/audio and MP3/WMA audio
(RPA Annual Meeting, March, 2008.)
This is free to RPA members. Please look at the RPA members only section on the RPA website for access instructions.
RPA: Year in Review
Alan Kliger, MD
RPA's Advocacy Agenda
Robert Blaser, MD
Brian Ling Lecture: Pay for Performance is Here! Lessons of success from Medicare Physician Payment Demonstration Project
Karl Ulrich, MD
ESA Payment Update: Where Knowledge Meets Politics
Alan Nissenson, MD
Value and Courage in Politics: Nephrology Reaches Farther
Rebecca Schmidt, MD
Value and Courage in Politics: Nephrology Reaches Farther
Larry Lehrner, MD
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
INTERVENTIONAL NEPHROLOGY: WHAT NEPHROLOGISTS SHOULD KNOW (Part 2 of 2)
Complications of Tunneled HD Catheters
Antoine L. Samaha, MD
Management of Catheter Infection
Bharat S. Sachdeva, MD
Peritoneal Dialysis Catheters: Peritoneoscopic Method
Stephen R. Ash, MD
Peritoneal Dialysis Catheters: Fluoroscopic Method
Ivan D. Maya, MD
Percutaneous Balloon Angioplasty Procedure
Alexander S. Yevzlin, MD
Management of Central Venous Stenosis
Florin N. Gadalean, MD
Hand Ischemia
Steven Wu, MD
Preservation of Veins?
Edgar V. Lerma, MD, FASN
Evaluation Stents: Do They Work?
Kenneth D. Abreo, MD
Vascular Access Center: What Does It Mean for You and What Does It Do for the Patient?
Donald Schon, MD
April 16th, 2008
Pre-ESRD and Mineral Metabolism
Kevin J. Martin, MB, BCh, BAO, FACP, and Sharon M. Moe, MD, FASN
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Martin: What is the time course of changes in 1,25D in patients with CKD as GFR falls? What are their 25D levels? How does nephrotic syndrome affect 25D levels? What is the animal data regarding use of calcitriol or other D-derivatives in models of CKD and/or renal injury? Does vitamin D protect or harm the kidney? What is the data in patients regarding vitamin D and progression of CKD? Moe: How does FGF-23 fit into the picture of mineral bone disorder? What is the most important action of FGF-23 in terms of renal osteodystrophy? How important are minor phosphorus elevations in normal patients and in patients with very mild CKD? How does serum Pi relate to cardiovascular events and progression in early CKD patients? What are the data regarding osteoporosis in CKD patients? What do bone biopsy data show? Is osteoporosis greater with hyperparathyroid bone disease or adynamic? What role does hypogonadism play? What is the new proposed KDIGO classification? What are the correlates of osteoporosis in CKD patients?
RRI Tenth International Conference on Dialysis, January, 2008. Part Two.
Flash slide/audio; MP3 audio
Heart rate variability and sympathetic function in CKD-implications for management
Christopher T. Chan, MD, FRCPC
Obesity in the dialysis patient - good or bad?
Jonas Axelsson, MD, PhD
Potential interventions in sepsis-related acute renal failure
Claudio Ronco, MD
Debate Part I CKD Stage V in the aged population (>70 yrs): dialysis or (low protein) diet?
Madhukar Misra MD, FACP
Debate Part II CKD Stage V in the aged population (>70 yrs): dialysis or (low protein) diet?
Giuliano Brunori, MD
(Renal Research Institute 10th International Conference. January, 2008.)
ANNA CE
(Article Free, $CE)ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.
Relationships Between Registered Nurse Staffing, Processes of Nursing Care, and Nurse-Reported Patient Outcomes in Chronic Hemodialysis Units
(Vol 35/No. 2. Expires 04/20/2010)
Charlotte Thomas-Hawkins, PhD, RN; Linda Flynn, PhD, RN; Sean P. Clarke, PhD, CRNP, FAAN
1.4 hr
The Self-Management Experience Of People with Mild to Moderate Chronic Kidney Disease
(Vol 35/No. 2. Expires 04/20/2010)
Lucia Costantini, MN, RN; Heather Beanlands, PhD, RN; Elizabeth McCay, PhD, RN; Daniel Cattran, MD; Michelle Hladunewich, MD; Daphene Francis, BScN, RN
1.5 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
INTERVENTIONAL NEPHROLOGY: WHAT NEPHROLOGISTS SHOULD KNOW (Part 1 of 2)
Vascular Anatomy: What Should Nephrologists Know about It?
Gerald A. Beathard, MD, PhD, FASN
Vascular Mapping: Is It Needed?
Arif Asif, MD
Sites and Types of Arteriovenous Fistulae
Gerald A. Beathard, MD, PhD, FASN
Early Arteriovenous Fistula Failure: Basic Biology and Hemodynamics
Prabir Roy-Chaudhury, MD, PhD, FASN
Fistula Maturation and Its Timing
Bhagwan D. Bhimani, MD
Vascular Access Surveillance: Detection of Access Malfunction
Anatole Besarab, MD
Salvage of an Immature Fistula
Jack Work, MD
Fistula Thrombosis and Thrombectomy Procedures
Naveen K. Atray, MD, FASN
Graft Thrombectomy: What is the Best Method?
Aris Q. Urbanes, MD
Creation of Secondary Fistula
Peter L. Miller, MD
Does Cannulation Make a Difference?
Deborah J. Brouwer, RN, CNN
Renal Ultrasound
W. Charles O'Neill, MD
March 31st, 2008
New Insights into Common Problems After Kidney Transplantation
Bertram L. Kasiske, MD and Jose R. Weisinger, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Kasiske: Which forms of cancer are increased after renal transplantation, and what explanations account for these increases? Are there any particular immunosuppressive regimens associated with a higher or lower incidence of cancer? If so, which ones? Weisinger: What characterizes post-transplant bone disease? What happens typically to parathyroid hormone? To serum phosphorus? Should the hypophosphatemia be treated? How are phosphatonins involved? What do we know from bone biopsy studies? What are reasonable short and long term strategies to minimize bone loss after transplantation? What evidence will KDIGO be reviewing in this area?
RRI Tenth International Conference on Dialysis, January, 2008. Part One.
Flash slide/audio; MP3 audio
What a nephrologist should understand about a dialysis machine
Richard A. Ward, PhD
How water quality & dialysate composition affect dialysis practice
Nicholas A. Hoenich, PhD
Understanding the Federal ESRD survey process: current issues & future directions
Judith Kari, MSSW
Understanding the finances of a dialysis facility and its medical director
Peter B. DeOreo, MD, FACP
How dialysis membranes can affect outcome - new developments
Norma Ofsthun, PhD
CASE DISCUSSION: A complex PD patient
Jose A. Diaz-Buxo, MD, FACP
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
GLOMERULONEPHRITIS UPDATE: DIAGNOSIS AND THERAPY (PART 2 OF 2) - 9 talks
ANCA Small Vessel Vasculitis
Patrick H. Nachman, MD
Diagnosis and Treatment of Anti-GBM Disease
Charles D. Pusey, DSc, FRCP
Case study : Treatment Issues in Rapidly Progressive Glomerulonephritis: Variations on Transatlantic Themes
Faculty
The Dysproteinemias
Stephen M. Korbet, MD, FASN
Current and New Treatments of Lupus Nephritis
Gerald B. Appel, MD, FASN
Thrombotic Microangiopathies
Gerald B. Appel, MD, FASN
Viral Glomerulonephritides: HIV, HBV, and HCV
Warren L. Kupin, MD
Case study : Management Cases in Lupus Nephritis, Viral Glomerulonephritis, and Dysproteinemias
Faculty
March 14th, 2008
Challenges and Opportunities in the Treatment of Hyperuricemia and Gout
Richard Johnson, MD (moderator); Robert Terkeltaub, MD; Michael W. Rich, MD; Daniel Feig, MD, PhD, MS
(ASN Renal Week Official Symposium, 2007).
Terkeltaub: What are the available treatments for gout? What is the mechanism of action of allopurinol? What are the cautions associated with its use? How is febuxostat different and possibly better? How do uricosurics work? Which ones are available? What are the pros and cons of uricases? Rich: Elevated uric acid is associated with poor cardiovascular outcomes. What evidence suggests that this may be causal? What were the findings regarding serum uric acid in the SHEP study? How does uric acid figure in studies of congestive heart failure or coronary artery disease? What do interventional studies using allopurinol tell us? Did the uricosuric effect of losartan affect outcomes in the LIFE study? Feig: What does a rat model of uricase inhibition show in terms of blood pressure and salt sensitivity? What does raising uric acid do to glomerular pathology? What is true of serum uric acid in essential hypertension in adolescents? What happens when you give half of them allopurinol?
New Treatments for Diabetes Mellitus: Implications for Clinicians
Robert Nelson, MD and George Bakris, MD
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Nelson: How do we treat diabetes with kidney disease in 2007? What does KDOQI recommend in terms of screening? Blood pressure targets? What are the current recommendations regarding ACE inhibitors and ARBs? What should the target HbA1C be? What protein intake? What LDL value? What are the trends in terms of obesity and diabetes in children? What does study of Pima Indians teach us? Bakris: What are the major classes of PPARs and what are their physiologic effects? Can thiazolidinediones (TZDs) actually prevent diabetes? What are the data in terms of diabetes progression? How do outcomes differ short term vs. long term? How useful are combinations of metformin plus TZDs, or sulfonylureas plus TZDs? What are the intermediate cardiovascular and lipid effects and effects on microalbuminuria? What did the PROactive trial show? Was the Nissen NEJM meta-analysis flawed? What are the current FDA recommendations and cautions?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
GLOMERULONEPHRITIS UPDATE: DIAGNOSIS AND THERAPY (PART 1 OF 2) - 9 talks
Management of the Nephrotic Syndrome
Gerald B. Appel, MD, FASN
Pathology and Pathogenesis of Minimal Change Disease and Focal Segmental Glomerulosclerosis
Helmut G. Rennke, MD
Membranous Nephropathy in 2007
Daniel C. Cattran, MD, FRCPC
Treatment of Focal Segmental Glomerulosclerosis
Stephen M. Korbet, MD, FASN
Case study : Treatment Issues in Focal Segmental Glomerulosclerosis
Faculty
Spectrum of Membranoproliferative Glomerulonephritis
Helmut G. Rennke, MD
Treatment and Pathology of Diabetic Nephropathy in 2007
J. Charles Jennette, MD; Jai Radhakrishnan, MD
IgA Nephropathy: 2007 Update
Richard J. Glassock, MD
Case study : Management Cases of Membranous, IgA Nephropathy, and Membranoproliferative Glomerulonephritis
Faculty
February 28th, 2008
Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains
David Bushinsky, MD (moderator); Geoffrey Block, MD, CCRI; Francisco Llach, MD; Rajnish Mehrotra, MD, FACP, FASN.
(ASN Renal Week Official Symposium, 2007).
Panel Discussion: What are the factors that promote vascular calcification in early CKD and in ESRD? How does vascular calcification affect prognosis? Should we screen for vascular calcification? If so, how? If yes, then how do we use this information? What should the target serum phosphate levels be as CKD progresses from stage 3 through 5? How good is the data suggesting lower phosphate targets? What are the various phosphate binder options available? Are they equally effective? Equally potent? Are there patient factors affecting choice of binder? To what extent should we control serum phosphate in predialysis patient? How should this be done? What are the key take-home points?
The Aging Kidney
Danilo Fliser, MD; George R. Aronoff, MD.
(ASN Renal Week Clinical Nephrology Conference, November, 2007.)
Fliser: How fast does GFR fall as we age? If GFR the best measure of renal function in the elderly? What other changes occur in the kidneys as we age? How is the fall in GFR related to comorbidity? To what extent is cystatin a better measure of GFR in the elderly? Aronoff: How do we approach drug dosing in the elderly? What happens to body composition and how does this affect dose? Is liver metabolism of drugs affected? If so, how? What about pharmacodynamics? What is the Beers list of drugs? Which drugs are best avoided in the elderly? What are practical ways of reducing drug exposure in this population?
ANNA CE
(Article Free, $CE)Learning from Stories of People with Chronic Kidney Disease
(Vol 35/No. 1. Expires 02/20/2010)
Anita E. Molzahn, PhD, RN; Anne Bruce, PhD, RN; Laurene Sheilds, PhD, RN
1.3 hr
Cognitive Function and Adherence of Older Adults Undergoing Hemodialysis
(Vol 35/No. 1. Expires 02/20/2010)
Debra J. Hain, DNS, ARNP, GNP, BC
1.4 hr
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 2 of 2)
Principles of Bioethics: Justifying Research
Bernard Lo, MD
Debate: Does Routine Screening of Dialysis Access Reduce Risk of Thrombosis?
Laura M. Dember, MD, FASN
Decision Analysis and Cost-Effectiveness Analysis: Taking It to Another Level
Neil R. Powe, MD, MPH, MBA, FASN
Genetic Epidemiology: A New Frontier
Donald W. Bowden, PhD
Putting It All Together: Journal Club #2
Kirsten L. Johansen, MD
Biostatistics Workshop Part #2: Everything You Always Wanted to Know About Biostatistics, But Were Afraid to Ask
Charles E. McCulloch, PhD
February 15th, 2008
Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions
Gérard M. London, MD (moderator): Craig B. Langman, MD; Markus Ketteler, MD.
(ASN Renal Week Official Symposium, 2007).
Langman: What is the pathogenesis of mineral bone disorder in CKD? As GFR falls, at what point does serum Pi increase? What is the comparative efficacy of currently used Pi binders? What's the association between serum Pi levels and cardiovascular risk in ESRD, stage 2-4 CKD, and stage 2 CKD? What percent have coronary calcification at onset of dialysis? What were the conclusions of the DCOR and RIND studies in terms of coronary calcification and survival in patients using sevelamer vs. calcium-containing binders? What are the new data concerning sevelamer carbonate? Ketteler: What is fibroblast growth factor 23, and what is its role in phosphate excretion as GFR falls? How does extracellular phosphate affect vascular smooth muscle biology? What are the pathways for activating vascular smooth muscle transformation into osteoblast phenotypes? What does fetuin-A do? How does sevelamer affect fetuin-A levels? What is the role of matrix Gla protein and pyrophosphate in preventing calcification?
Challenges in Volume Management. Optimizing Care in Patients with Heart Failure and Renal Dysfunction
John C. Burnett, MD; Michael B. Fowler, MBBS, FRCP; Mihai Gheorghiade, MD
(ASN Renal Week Official Symposium, 2007).
Burnett: What is the prevalence of CKD in patients with CHF? What is the cardiorenal syndrome? What are its principal mechanisms? How are ANP and BNP involved? How is BNP activation impaired in CHF? How are aldosterone and AVP involved in heart failure? Fowler: Which of the common pharmacologic treatments for heart failure impact on survival and other hard outcomes? Digoxin? Diuretics? Beta-blockers? ACE-I, ARB? Aldosterone blockers? Nitrates-hydralazine? Do implantable defibrillators improve survival? What is the risk-predictive value of a widened QRS interval? What is cardiac resynchronization therapy? What are new treatment methods on the horizon, including vasopressin antagonists, adenosine antagonists, aliskiren, and newer intotropic agents? Gheorghiade: What is the role of pulmonary congestion in heart failure? What are the therapeutic options? How do treatments with diuretics vs. vasopressin antagonists differ in terms of effects on urinary parameters and serum sodium? What is the prognostic importance of hyponatremia in heart failure? What do the treatment trials with vasopressin antagonists, especially using tolvaptan, show in terms of both intermediate and hard outcomes?
Cardiovascular Disease in End Stage Renal Disease Patients
William L. Henrich, MD, MACP.
(ASN Board Review Course, August, 2007.)
Henrich: What are the main cardiovascular risks in patients with CKD? What are the proposed mechanisms of LVH, including concentric and eccentric hypertrophy, and systolic and diastolic dysfunction? What are the causes for sudden death? What is the role of myocardial intermyocyte fibrosis? What did the fosinopril and ramipril trials show? Are biomarkers useful? Why was the 4-D trial negative? Are statins useful in early CKD? What is the role for carvedilol? More frequent dialysis? Is there an advantage for CABG over stents in ESRD patients? What are the basic management guidelines for cardiovascular disease in CKD patients?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICALLY APPROACHING THE LITERATURE: APPLYING THE PRINCIPLES OF EPIDEMIOLOGY AND BIOSTATISTICS (Part 1 of 2)
E is for Epidemiology: The Key Principles
Harold I. Feldman, MD, FASN
Case-Control Studies: Low Cost/High Impact
Rulan S. Parekh, MD, FASN
Cohort Studies: From the Beginning to the End
Ravi I. Thadhani, MD, MPH
Randomized Controlled Trials: Good as Gold
Christoph Wanner, MD
Biostatistics Workshop Part #1: How Things Actually Work
Tom H. Greene, PhD
Biostatistics Workshop Part #2: How Things Actually Work
Tom H. Greene, PhD
Meta-Analysis: When One is Not Enough
Amit Garg, MD, PhD
Putting It All Together: Journal Club #1
Mary B. Leonard, MD
January 30th, 2008
Contrast Media and CKD: What You Should Know About Contrast-Induced Nephropathy and Nephrogenic Systemic Fibrosis
Norbert Lameire, MD (moderator); Pontus B. Persson, MD, PhD; Michael V. Knopp, MD, PhD; Mark A. Perazella, MD
(ASN Renal Week Official Symposium, 2007).
Persson: What is the definition of contrast-induced nephropathy (CIN)? How can an acute decrease in GFR result in a creatinine elevation that peaks several days later? Is it the osmolality of these agents or their viscosity that's at fault? How do they cause renal damage? How do the affect blood flow through the vasa recta? Tubuloglomerular feedback? What is the osmolality and viscosity of commonly used contrast agents? What do clinical studies tell us? Why is renal failure lower with a low-osmolar, but above iso-isosmolar, agent (ioxaglate) compared to an isosmolar agent (iodixanol)? Knopp: What are the choices of imaging procedures in renally impaired patients? How do we use them to assess morphology and function? What are the main categories of MR contrast agents? Perazella: How is nephrogenic systemic fibrosis (NSF) defined? When was it first noticed? What are the symptoms? What parts of the body are affected? Which parts are spared? What are predisposing causes? Does it occur in stage 1-4 CKD? How do we diagnose NSF? With which MR agents is it most common? Least common? What guidelines can we follow in using these agents?
New Developments in Anemia Management in Chronic Kidney Disease
Dr. Adeera Levin, MD (moderator): Cindy Roy, PhD; Anatole Besarab, MD; Richard Amerling, MD, Arnold Berns, MD (discussant)
(ASN Renal Week Official Symposium, 2007).
Roy: How dose iron cycle through the various organs? Where does hepcidin get involved? What is ferroportin? What does hepcidin to to macrophage transport of iron? To iron absorption? What can we learn from transgenic rat models?
Besarab: How has our target Hb evolved as guidelines have been issued over the past 10 years? What is the FDA target? The 2007 KDOQI target? What did the Normalized Hemoglobin Trial, CREATE, and CHOIR show? How can we achieve Hb targets while minimizing cycling? What does KDOQI recommend in patients with ferritins greater than 500? What happened in the DRIVE study, where iron was given to patients with ferritins of 500-1200 ng/mL?
Amerling: When 1 g of ferric gluconate was given to 80 dialysis patients with serum ferritins ranging from 100 - 1500 ng/mL, what where the results on Hb, TSAT, and serum ferritin? What effect did this have on ESA dose?
The Cystic Diseases
William M. Bennett, MD.
(ASN Board Review Course, August, 2007.)
Bennett: What are the basis of PKD genetics? Clinically, how do ADPKD1, ADPKD2, and ARPKD differ? How do we diagnose PKD? When are ultrasounds falsely negative? Genetic tests? What part of the cell is affected by polycystin? What is the 2-hit theory? What are the renal complications? How should hypertension be treated? What are the cerebrovascular and cardiovascular complications? When should we screen for CV aneurysms? What are the liver and GI complications? What did we learn from the CRISP study about progression? What are the new treatments for PKD? what conditions can cause similar cystic disease in the kidney? What other renal cystic diseases are of importance?
(Columbia University Nephrology and Pathology Faculty; January, 2008)
A middle-aged Hispanic male had with history of incarceration, occupation as a welder, heroin abuse, presented with proteinuria 3.4 g/day and microhematuria. No DM. Mild HTN. Normal sized kidneys. Negative serological tests. Initial DDx: Membranous, IgA, FSGS. Discussion focus: Hint: IgG deposits were found.
(Edited by Jai Radhakrishnan, MD). (more...)
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 2 of 2)
Defining AKI
Ravindra L. Mehta, MD, FASN
Pathophysiology of AKI
Bruce A. Molitoris, MD
Pharmacologic Therapy for AKI
Mark D. Okusa, MD, FASN
Contrast-Induced Nephropathy
Paul M. Palevsky, MD, FASN
Abdominal Compartment Syndrome
Lakhmir S. Chawla, MD
Renal Replacement Therapy in AKI: When, What, and How Much
Paul M. Palevsky, MD, FASN
The Hybrid Renal Replacement Therapies
Mark R. Marshall, MBChB
Technical Issues for the Delivery of RRT in the ICU
Paul M. Palevsky, MD, FASN
Pediatric AKI
Stuart Goldstein, MD
Drug Dosing in AKI
Bruce A. Mueller, PharmD
Treatment of Poisonings
David S. Goldfarb, MD, FASN
January 15th, 2008
Navigating the Erythropoietin Stimulating Agent Landscape in CKD-Related Anemia
Jeffrey S. Berns, MD, FASN; Robert Provenzano, MD; Lynda Szczech, MD. (Moderator: Jeffrey S. Berns, MD)
(ASN Renal Week Official Symposium, 2007).
Berns: What does the recent literature show? CHOIR, CREATE, ACORD, MacDougall, and the 2007 KDOQI workgroup meta-analyses?
Provenzano: How were these issues discussed at the Cardiovascular and Renal Drugs Advisory Committee on ESAs? What were the votes regarding each practice recommendation? What were open questions?
Szczech: Now that the FDA has mandated new black box warnings on ESAs, how does impact our use of these agents? How can we minimize potential side effects of ESAs? What might be our triggers for action? What should the initial dosages be, and when should doses be reduced or held?
Critical Care Nephrology
Patrick Murray, MD.
(ASN Board Review Course, August, 2007.)
Murray: How do we hemodynamically manage sepsis in terms of MAP, CVP, urine output, and mvO2? How can we optimize renal perfusion? Is there evidence that any of the inotropes are better? What should the target MAP be? What are the results regarding vasopressin? Drotrecogin alpha? Corticosteroid use? What is the ideal ventilator strategy, and what are the main pulmonary-renal syndromes? What do the data show about dry vs. wet management?
ANNA CE
Lecture Free
Free CE
Chronic Kidney Disease - Mineral Bone Disorder
Jose A.L. Arruda, MD, FASN; Jennifer L. Snavely, CRNP-BC, MSN, CNN)
(ANNA Fall Meeting, San Francisco, CA. October, 2007.) 1.25 CE
Arruda: What do observational data suggest about desirable levels of serum PTH, calcium, and phosphorus in CKD patients? What do the vitamin D studies show? Are the analogues different from calcitriol in terms of survival? When is cinacalcet indicated? How does vascular calcification relate to mortality? What did the Treat-to-Goal, RIND, and DCOR studies tell us about calcium-containing phosphate binders versus sevelamer? Snavely: How do we define CKD-Bone Mineral Disorder? As CKD progresses, when do changes in calcium, phosphorus, and PTH occur? How is vitamin D involved? What to the KDOQI clinical practice guidelines suggest in terms of managing elevated PTH as GFR falls? When should we give vitamin D and in what form? What are the practice barriers in addressing bone mineral disorders in CKD patients?
ASN Renal Week 2007
now in MP3AUDIOFILE LIST (Renal Week 2007)
2007 Renal Week PGE Course:
CRITICAL CARE NEPHROLOGY: 2007 UPDATE (Part 1 of 2)
Ventilators 101: What the Non-Intensivist Needs to Know
Patrick T. Murray, MD, FASN
Acute Lung Injury/ARDS
Kathleen D. Liu, MD
Hemodynamic Monitoring and Volume Management
Lakhmir S. Chawla, MD
Approach to Shock, Vasopressors, and Natriuretic Peptides
Kathleen D. Liu, MD
Advances in the Treatment of Severe Sepsis and Septic Shock
Patrick T. Murray, MD, FASN
An Update on Congestive Heart Failure
Kiran K. Khush, MD
Update in Coagulation: Cell Mediated Coagulation and New Anticoagulants
Lakhmir S. Chawla, MD
Current State of Acute Brain Injury Management
Andrew Davenport, MD
Ethics in the ICU: When Can You Say No?
Douglas B. White, MD, MAS
HDCN home /about our site / subscribe to key zone / register for free zone
update email
address / subscription status / forget your
password?
